A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be ...
Zacks Investment Research on MSN
NVO down 42% year to date: Is this an indication to sell the stock?
Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply ...
A peripherally acting cannabinoid receptor 1 antibody combined with semaglutide induced significant weight loss for adults ...
Danish pharma major Novo Nordisk has announced the launch of Ozempic (injectable semaglutide) in India. The popular ...
For Elizabeth Honigsberg, a general and bariatric surgeon and obesity and weight management specialist at Dartmouth Hitchcock Medical Center in Lebanon, combating obesity and the misconceptions that s ...
Schizophrenia spectrum disorders significantly increase cardiovascular and metabolic disease risks, partly due to antipsychotic-induced weight gain and glucose dysregulation.
The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...
Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with ...
Tantalizing results from small trials and anecdotes raised hopes that drugs like Ozempic could help. Despite setbacks, ...
Inflammation likely plays a key role in T2D outcomes, and various anti-inflammatory treatments may improve both T2D and its ...
Recently, the Delhi High Court refused to grant an interim injunction sought by Novo Nordisk, noting concerns of possible ...
Discover why Wave Life Sciences Ltd. is a high-risk, high-reward biotech with unique RNA therapies for AATD, obesity, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback